Angela Abicht1,2, Ulrike Schön1, Andreas Laner1, Elke Holinski-Feder1, Isabel Diebold1,3. 1. Medical Genetics Center, Munich, Germany. 2. Department of Neurology, Friedrich-Baur-Institute, Klinikum der Ludwig-Maximilians-University, Munich, Germany. 3. Department of Pediatrics, Technical University of Munich School of Medicine, Munich, Germany.
Abstract
BACKGROUND: Comprehensive genetic analysis yields in a higher diagnostic rate but also in a higher number of secondary findings (SF). American College of Medical Genetics and Genomics (ACMG) published a list of 59 actionable genes for which disease causing sequence variants are recommended to be reported as SF including 27 genes linked to inherited cardiovascular disease (CVD) such as arrhythmia syndromes, cardiomyopathies and vascular and connective tissue disorders. One of the selected conditions represented in the actionable gene list is the arrhythmogenic right ventricle cardiomyopathy (ARVC), an inherited heart muscle disease with a particularly high risk of sudden cardiac death (SCD). Since clinical symptoms are frequently absent before SCD, a genetic finding is a promising option for early diagnosis and possible intervention. However, the variant interpretation and the decision to return a SF is still challenging. METHODS: To determine the frequency of medically actionable SF linked to CVD we analyzed data of 6,605 individuals who underwent high throughput sequencing for noncardiac diagnostic requests. In particular, we critically assessed and classified the variants in the ARVC genes: DSC2, DSG2, DSP, PKP2 and TMEM43 and compared our findings with the population-based genome Aggregation Database (gnomAD) and ARVC-afflicted individuals listed in ClinVar and ARVC database. RESULTS: 1% (69/6,605) of tested individuals carried pathogenic SF in one of the 27 genes linked to CVD, of them 13 individuals (0.2%) carried a pathogenic SF in a ARVC gene. Overall, 582 rare variants were identified in all five ARVC genes, 96% of the variants were missense variants and 4% putative LoF variants (pLoF): frameshift, start/stop-gain/loss, splice-site. Finally, we selected 13 of the 24 pLoF variants as pathogenic SF by careful data interpretation. CONCLUSIONS: Since SF in actionable ARVC genes can allow early detection and prevention of disease and SCD, detected variant must undergo rigorous clinical and laboratory evaluation before it can be described as pathogenic and returned to patients. Returning a SF to a patient should be interdisciplinary, it needs genetic counselling and clinicians experienced in inherited heart disease. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: Comprehensive genetic analysis yields in a higher diagnostic rate but also in a higher number of secondary findings (SF). American College of Medical Genetics and Genomics (ACMG) published a list of 59 actionable genes for which disease causing sequence variants are recommended to be reported as SF including 27 genes linked to inherited cardiovascular disease (CVD) such as arrhythmia syndromes, cardiomyopathies and vascular and connective tissue disorders. One of the selected conditions represented in the actionable gene list is the arrhythmogenic right ventricle cardiomyopathy (ARVC), an inherited heart muscle disease with a particularly high risk of sudden cardiac death (SCD). Since clinical symptoms are frequently absent before SCD, a genetic finding is a promising option for early diagnosis and possible intervention. However, the variant interpretation and the decision to return a SF is still challenging. METHODS: To determine the frequency of medically actionable SF linked to CVD we analyzed data of 6,605 individuals who underwent high throughput sequencing for noncardiac diagnostic requests. In particular, we critically assessed and classified the variants in the ARVC genes: DSC2, DSG2, DSP, PKP2 and TMEM43 and compared our findings with the population-based genome Aggregation Database (gnomAD) and ARVC-afflicted individuals listed in ClinVar and ARVC database. RESULTS: 1% (69/6,605) of tested individuals carried pathogenic SF in one of the 27 genes linked to CVD, of them 13 individuals (0.2%) carried a pathogenic SF in a ARVC gene. Overall, 582 rare variants were identified in all five ARVC genes, 96% of the variants were missense variants and 4% putative LoF variants (pLoF): frameshift, start/stop-gain/loss, splice-site. Finally, we selected 13 of the 24 pLoF variants as pathogenic SF by careful data interpretation. CONCLUSIONS: Since SF in actionable ARVC genes can allow early detection and prevention of disease and SCD, detected variant must undergo rigorous clinical and laboratory evaluation before it can be described as pathogenic and returned to patients. Returning a SF to a patient should be interdisciplinary, it needs genetic counselling and clinicians experienced in inherited heart disease. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
Entities:
Keywords:
Secondary findings; arrhythmogenic right ventricle cardiomyopathy; variant interpretation
Authors: Jamie D Kapplinger; Andrew P Landstrom; Benjamin A Salisbury; Thomas E Callis; Guido D Pollevick; David J Tester; Moniek G P J Cox; Zahir Bhuiyan; Hennie Bikker; Ans C P Wiesfeld; Richard N W Hauer; J Peter van Tintelen; Jan D H Jongbloed; Hugh Calkins; Daniel P Judge; Arthur A M Wilde; Michael J Ackerman Journal: J Am Coll Cardiol Date: 2011-06-07 Impact factor: 24.094
Authors: Anneline S J M te Riele; Cynthia A James; Judith A Groeneweg; Abhishek C Sawant; Kai Kammers; Brittney Murray; Crystal Tichnell; Jeroen F van der Heijden; Daniel P Judge; Dennis Dooijes; J Peter van Tintelen; Richard N W Hauer; Hugh Calkins; Harikrishna Tandri Journal: Eur Heart J Date: 2015-08-27 Impact factor: 29.983
Authors: G McKoy; N Protonotarios; A Crosby; A Tsatsopoulou; A Anastasakis; A Coonar; M Norman; C Baboonian; S Jeffery; W J McKenna Journal: Lancet Date: 2000-06-17 Impact factor: 79.321
Authors: Torsten B Rasmussen; Johan Palmfeldt; Peter H Nissen; Raffaela Magnoni; Søren Dalager; Uffe B Jensen; Won Y Kim; Lene Heickendorff; Henning Mølgaard; Henrik K Jensen; Ulrik T Baandrup; Peter Bross; Jens Mogensen Journal: Hum Mutat Date: 2013-03-11 Impact factor: 4.878
Authors: Susan M Wolf; Brittney N Crock; Brian Van Ness; Frances Lawrenz; Jeffrey P Kahn; Laura M Beskow; Mildred K Cho; Michael F Christman; Robert C Green; Ralph Hall; Judy Illes; Moira Keane; Bartha M Knoppers; Barbara A Koenig; Isaac S Kohane; Bonnie Leroy; Karen J Maschke; William McGeveran; Pilar Ossorio; Lisa S Parker; Gloria M Petersen; Henry S Richardson; Joan A Scott; Sharon F Terry; Benjamin S Wilfond; Wendy A Wolf Journal: Genet Med Date: 2012-04 Impact factor: 8.822
Authors: Robert C Green; Jonathan S Berg; Wayne W Grody; Sarah S Kalia; Bruce R Korf; Christa L Martin; Amy L McGuire; Robert L Nussbaum; Julianne M O'Daniel; Kelly E Ormond; Heidi L Rehm; Michael S Watson; Marc S Williams; Leslie G Biesecker Journal: Genet Med Date: 2013-06-20 Impact factor: 8.822
Authors: Domenico Corrado; Thomas Wichter; Mark S Link; Richard N W Hauer; Frank E Marchlinski; Aris Anastasakis; Barbara Bauce; Cristina Basso; Corinna Brunckhorst; Adalena Tsatsopoulou; Harikrishna Tandri; Matthias Paul; Christian Schmied; Antonio Pelliccia; Firat Duru; Nikos Protonotarios; Na Mark Estes; William J McKenna; Gaetano Thiene; Frank I Marcus; Hugh Calkins Journal: Circulation Date: 2015-07-27 Impact factor: 29.690
Authors: Emily Olfson; Catherine E Cottrell; Nicholas O Davidson; Christina A Gurnett; Jonathan W Heusel; Nathan O Stitziel; Li-Shiun Chen; Sarah Hartz; Rakesh Nagarajan; Nancy L Saccone; Laura J Bierut Journal: PLoS One Date: 2015-09-02 Impact factor: 3.240